

Experience of 20 years in Management of Medulloblastoma (A long – term Retro spective study)

By

Dr. Alaa Abdel Hay (MD), Manal Moawad(MD)**

Hussein Boushnak (MD)* and Hohamed Kabil***

*Neurosurgical, **Radiation Oncology and General Surgery. Departments, Faculty of Medicine - Ain Shams University

Abstract :

Treatment for patients with newly diagnosed medulloblastoma includes surgical resection followed by craniospinal radiotherapy. Adjuvant chemotherapy has been shown to increase the cure rate with high risk or average risk disease and is now a standard part of contemporary management (*Gajjar et al., 99*).

Advance in surgery and radiotherapy techniques have improved results in the last few decades (*Packer 1999*). These procedures have important early and long term morbidity that must be weighted in order to offer the patient an acceptable risk-benefit likelihood.

The purpose of this study was to analyze the various clinical and prognostic features which might affect the survival of medulloblastoma and to asses the response of patients to treatment.

This study includes 288 patients with medulloblastoma who were treated in both Neurosurgical and Radiation Oncology Departments during the period 1981 and 2000.

Statistical analysis has proven that the median survival was not affected significantly by the sex or site of tumor but the most significant variables that affected the median survival were the extent of surgery and stage of the tumor, age and histopathology. Shunt operation reduces the incidence of post operative mortality markedly.

Introduction:

Medulloblastoma constitutes from 10% to 20% of primary CNS tumors in children and about 40% of all posterior fossa tumors (*Heideman et al., 1997*).

Surgical removal of the tumor is considered the first step of treatment to establish definite diagnosis, relieve the acute symptoms and reduces the bulk of tumor (*Brandes et al., 1999*). Total or near total resection exerts an important influence on recurrence of medulloblastoma (*Bailey et al., 1995*).

The prognosis for medulloblastoma has improved remarkably in the past 40 years as a consequence of advances in radiotherapy (*Brandes et al., 1999*).

In 1994, *Carr et al.*, reported a trend of better survival in adult patients treated with chemotherapy meanwhile adjuvant chemotherapy was of value if given for patients with high risk of recurrence (*Brandes et al., 1999*).

Recently *Millot et al., 1999*, reported encouraging results with the

use of high dose chemotherapy with stem cell support after surgical resection and craniospinal irradiation for newly diagnosed medulloblastoma patients in high risk group.

Patients & methods

The medical records of patients with medulloblastoma treated in both Neurosurgery and Radiation Oncology Departments, Ain Shams University during the period 1981 and 2000. Medical records were studied those with incomplete data or lost follow up before ending prescribed treatment were excluded.

The studied patients were classified into two groups according to their age, group I, included 200 patients below or equal to 16 years, and group II, included 88 patients above 16 years of age.

The following criteria were studied:

1. Personal and medical history,
2. General and neurological examination.
3. Performance status according to Karnofsky scales
4. Radiological studies with either CT scan or MRI or both.
5. Histopathological examination & CSF cytology
6. Staging according to Chang staging system.
7. Details of different treatment modalities.
8. Toxicity and morbidity of treatment according to WHO system.
9. Survival was calculated from first day of treatment to the last follow up

All the studied different parameters were analyzed statistically to find out the most important prognostic factors affecting the median survival. Three year cumulative survival was estimated

and analyzed versus the various prognostic factors including age at diagnosis, sex, duration of symptoms and signs, CSF cytology histopathological results, site, stage of tumor, extent of surgical intervention and post operative therapy.

Results

For a convenient statistical approach and conclusive analysis of the obtained results, it was crucial to separate the studied patients into 2 groups below or equal and above 16 years. The mean survival for all cases was $26.4 + 15.9$ months.

The range of age for the studied patients was 3-29 years, the majority of patients were in pediatric group (200 patients) Male to female ratio was 1.4 : 1.

The duration of symptoms prior to diagnosis ranged between 1 to 6 months, with a mean value of $3.5 + 1.7$ months.

The main presenting symptoms were those of increased intracranial tension (headache, vomiting and blurring of vision) in 80% patients followed by incoordination 72% and cranial nerves affection 55%.

CSF cytology was done in 182 patients only and it was positive in 26%. (47/182).

Histopathology analysis of 130 cases, desmoplastic variant was described in 28.5% of them meanwhile the remaining was classic form.

The site of tumor was midcerebellar in 57% but lateral cerebellar tumor was found in 43%.

T. Staging was done according to Chang et al., 1969 staging system, T3 and T4 cases were significantly higher in both age groups (66%). Radiological findings by C.T. revealed that the highest majority of patients had a large tumor associated with obstructive

hydrocephalus ranging between moderate (32%) and severe degrees (68%). Perifocal edema was evident in 70% the tumor was hyper dense in 81% of patients.

↳ Treatment modalities done (surgery, radiotherapy and chemotherapy).

↳ Surgery includes biopsy, partial resection and total resection with or without shunt operation

↳ Toxicity and morbidity of treatment

1. Surgery: was the first line of treatment for all cases in the form of either total excision or subtotal excision. Gross total excision was performed for 82 patients (28%) in whom were shunted preoperatively (64 patients). Subtotal excision was performed for 186 patients (64.5%). The shunt was done for 43 of them. Meanwhile shunt operation was done with no tumor surgery for 20 patients only (7%) of all patients

2. Radiation therapy: Craniospinal radiation therapy was performed for all cases, with either Co 60 or linear accelerator 4 MV. Craniospinal radiation was given for all cases using either Co60 or linear accelerator 4Mv. With dose ranging 3600 to 5400 cGy to the posterior fossa and from 2000 to 3000 cGy according to the age of patients.

3. Chemotherapy was given for recurrent cases only (50 cases) in the form of CCNU vincristine and Natulan. unfortunately most of cases died after 2 or 3 courses.

Recurrence or progression of tumor were recorded in 68% of the cases. Extra - CNS metastasis included long bones, lymph nodes and liver occurred in 18 cases (10%) The commonest site of recurrence was at the primary tumor site (97%) followed by spinal metastases (18%).

Median Survival analysis:

Older age group showed significant higher median survival compared to younger age group ($P < .05$). but patients younger than 4 years old had poor median survival.

Sex did not significantly affect survival the symptoms prior to diagnosis ranged between 1 to 6 months, with a mean value of 3.5 + 1.7 months. so that most of cases were T_3 & T_4 .

Desmoplastic type was evident in 15% of younger age group and 55.8% in older one with significantly higher median survival for desmoplastic type in comparison to classic varian type ($P < 0.05$)

The commonest site of medulloblastoma in group I was the cerebellar vermis (62%) meanwhile the commonest site for group II was the lateral cerebellar region 53% with median survival 35.01 and 36 respectively which was not significant.

The median survival for T_1 & T_2 patient was significantly higher than those with T_3 & T_4 patients Pvalue was highly significant ($P < 0.01$).

The cumulative survival calculated for patients with statistical comparison for the extent of surgery in each group showed a high significant in the survival of the shunted patient ($P = < 0.01$) due to decrease in post operative mortality and morbidity of treatment. On the other hand, statistical

Comparison calculated for 207 patients who were all shunted, showed a highly significant increase in favor of total excision versus biopsy or subtotal excision ($P < 0.01$).

Discussion

The current study demonstrates that medulloblastoma patients constitute 10% of all primary malignant tumors referred to Radiation Oncology

Department of Ain Shams University

In a study NEMROCK, Egypt, between 1981, 1998 the incidence was 8.4% (*Helmy et al., 2000*) which was similar to that reported by Hadad *et al.*, in 1986 (8.5%). However lower incidence was reported by *Poldnak and Flammery in 1995*.

The age of studied patients ranged between 3 to 29 years with a mean age of 11.3 years. 70% of the cases were below 16 years similar to that reported by *Sheikh and Kanaam, 1997 . and Hadad et al., 1986* which was 10.1 years and Walpren and Friedman 1996, which was 11.3 years.

In this work, medulloblastoma constitute 23% of all primary brain tumor in pediatric age group which is nearly similar to that reported *Weidman et al. 1997* which was 20%.

According to Chang staging system, 34% of the analyzed cases were classified as T₁ and T₂ and 66% of them were T₃ and T₄ stages. However Zelter *et al.*, 1999, reported that 59% of 188 cases were T₁ and T₂ while 41% were T₃, T₄. The higher percentage of advanced cases in Egypt may be explained by the delayed presentation to physician.

Analysis of histopathological reports showed a significantly median survival for desmoplastic type. On the other hand, Aragones *et al.*, 1994, reported 5-year survival in desmoplastic variant compared to the classic type.

Histopathological study revealed that the desmoplastic type represented 15% of patients of younger age group but it was 55.8% in the older group in comparison to the classic type.

Histopathological variant in our study had significant higher median survival in favor to desmoplastic type ($P < 0.05$). Nevertheless, both *Sheikh and Kanan, 1994, and Ildan et al.,*

1994, considered desmoplastic type a favorable prognostic factor.

Disease free survival for the high risk group of patients was 20% meanwhile for the low risk group was 50%.

Diagnosis of medulloblastoma was mainly carried by computerized axial tomography in the first 10 years of the study (*Moawad, et al., 1987*).

As regard surgical intervention, patients were divided in to two main groups either shunted or non shunted group which were subdivided into subgroups according to the extent of surgery.

Statistical comparison of the median cumulative survival between shunted and non shunted patients in both surgical groups (total subtotal/biopsy groups) revealed a highly significant prolongation in the median survival $P < 0.01$ in patients who underwent shunt operation. This has been shown by *Salama et al., 1986* as well as *Moawad et al., in 1987*. Stating that CSF shunt had reduced dramatically post operative mortality from 46% to 11% and improved the survival of patients. Which was in contrast to that reported; *Bloom and Bessel, 1989*, preoperative shunt was advised to be avoided as a source of dissemination. In this report they suggested that shunt operation might be a chance for tumor dissemination and better to be avoided

From the analysis of previous results, it could be concluded that total excision with pre-operative shunting is the optimum modality as compared with minimal excision of the tumor. This findings agree with those reported by *Boyett et al., 1995, and Baily et al., 1995*.

Recently, Zeleter *et al., 1999* had also encouraged aggressive resection of the tumor of the tumor in their study of 188 patients.

Experience of 20 years in Management of Medulloblastoma

The median survival of patients with medulloblastoma has been reported to have increased significantly in the last decade which is mainly due to improvement of techniques including the entire cranial spinal axis irradiation and increasing the dose to the reurocranium and to the posterior possa., as well as improvement of diagnostic technique (CT & MR1). Together with the new trend of more radiacl resection aided by advances in microneurosurgery as well as improvement in the techniques of post operative radiation using computer planing system with simulation and the

use of linear accelerator with multiple energies (*Brandes et al., 1999*).

Inspite of improvement in the survival of the patients with medulloblastoma as a response to radiotherapy a wide range of short and long term side effects are reported *Branches et al., 1999*. Bone growth reladation, behavioral and inlelectual dysfunction and pituitary hypo thalamic dysfunction have been widely reported.

It could be concluded that the optimum surgery together with the adjuvant radiation therapy, are the main reasons behind prolongation and better quality of the long-term survival of patients with medulloblastoma.

Table (1) Clinical and pathological findings of 288 patients with medulblastoma

Age			
Below 16 ys	200		(69.4%)
Above 16 ys	88		(30.6%)
Mean age	[11.3 yrs (136 + 90.58 months)]		
Sex			
M	160		(55.6%)
F	128		(44.4%)
Symptoms of ↑ ICT.	230		(80%)
Incoordination	207		(72%)
Cranial N. Palsy	158		(55%)
CSF Cytology	(182)		
+ ve	47		(25%)
- ve	135		(75%)
Histopathology analysis	(130)		
Desmoplastic	37		(29%)
Non Desmoplastic	93		(71%)
Site of tumor			
Mid Cerebellar	165		(57%)
Lat Cenchbellar	123		(43%)
Stage			
T ₁ , T ₂	99		(34%)
T ₃ , T ₄	189		(66%)

Table (2) Surgical Treatment Modalities of 288 cases with Medulloblastoma.

a) Shunted group:	(209)	
Total excision	(64)	(31%)
Subtotal excision, biopsy	(125)	(60%)
Shunt only	(20)	(9%)
b) Non Shunted group	(79)	
Total excision	(18)	(22%)
Subtotal excision, biopsy	(61)	(78%)

Table (3) Radiological findings in 288 cases with medulloblastoma

Finding	Number	%
Hydrocephalic changes		
moderate	92	32%
severe	196	68%
Perifocal edema	202	70%
Density before contrast		
Hyperdense	233	81%
Isodense	20	7%
Hypodense	35	12%
Enhancement after contrast.		
Positive	228	79%
Negative	60	21%
Cystic areas and heterogeneity	32	11%
Calcification	17	6%

Table (4): Correlation of important prognostic factors versus 3-year survival for 153 patients with medulloblastoma

	No	Cummulative survival at 36M.	Median survival	P.Value
Age				
< 16 years	108	0.0535	31.51	Sig. <0.05
> 16 years	45	0.1967	36+	
Sex.				
Male	83	0.1117	36+	Non Sig.
Female	70	0.0762	36+	
Histopathology				
Desmoplastic	12	0.2857	36+	Sig. <0.05
Non-Desmoplastic	60	0.0375	31.41	
Site of tumor				
Cerebellar vermis	94	0.1016	35.01	N.S.
Lateral cerebellar	59	0.0813	36+	
Staging				
T1, T2	59	0.1823	36+	H.S. <0.01
T3, T4	94	0.0237	29.45	
Surgery				
Biopsy subtotal	52	0.0423	22.16	H.S. <0.01
Total resection	60	0.1024	36+	

* The remaining patients had insufficient follow up.

Experience of 20 years in Management of Medulloblastoma

Table (5) Complications of external radiations in 153 patients with Medullablastoma.

Complications	Number	%
< Early complications:		
Alopecia	153	100%
Myelosuppression On top of spinal nadiation	38	22%
Otitis media	20	13%
< Late complications		
Growth Hormonal Deficiency	29	19%
Decrease in the inellectual dysfunction	31	20%

Fig I : Cummulative Survival in 288 Patients wrth medulloblastoma as regard the age






Fig II : C ummulative Survival in 288 Patients wrth medulloblastoma as regard stage



FigI : Cummulative Survival in 288 Patients wrth medulloblastoma as regard tyvse of surgesy



References

- Aragones P, Magallon R, Piqueras C et al., (1994):** Medulloblastoma in adulthood: Prognostic factors influencing survival and recurrence. *Acta Neurochir*, 27: 65-68.
- Bailey CC, Gnekow A, Wellek S, Jones M, Round C, Brown J, Phillips A and Neihardt MK (1995):** Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma international society of pediatric Oncology and the German Society of Pediatric Oncology, *Med. Ped. Onc*, 25: 166.
- Bailey P and Cushing H (1925):** Medulloblastoma cerebelle: A common type of midcerebellar glioma of childhood. *Arch. Neurol Psychiatr*, 14: 192.
- Bloom HJ, Bessel EM (1989):** Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981. *Int J Radiation Oncology Biol Phys* 1989, 18: 763-772.
- Boyett J, Zeltzer P and Finlay J (1995):** Prognosis-free survival (PFS) and risk factors for primitive neuroectodermal tumors (PNET) of posterior fossa (PF) Medulloblastoma in children: report of the children cancer group (CCSG) randomized trial, CCSG-921. *Proc. Am. Soc. Clin Oncol*; 14: 147 Abstract.
- Brandes AA, Palmisano V and Monfardini S (1999):** Medulloblastoma in adults: clinical characteristics and treatment. *Cancer Treat Reviews*, 25: 3-12.
- Carrie C, Lasset C, Alapetite C, Haie Meder C et al., (1994):** Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 165 patients. *Cancer* 74: 2352.
- Haddad SM, Moustafa H, El Ghoneimy E et al., (1986):** Clinical study and results of treatment

- medulloblastoma. Egy. J of Radiology and Nuclear Medicine, 17: 165.
- Grajjar AJ, Heideman RL, Douglass EC et al., (1993):** Relation of tumor cell ploidy to survival in children with medulloblastoma. J Clin Oncol; 11: 2211.
- Halperin EC and Friedman HS (1996):** Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis, Cancer; 78: 874.
- Heideman RL, Packer RJ, Allbright LA et al., (1997):** Tumors of the CNS. In Pizzo PA, Poplack DG (eds): Principles and practice of pediatric Oncology 3rd Ed. Lippincott Raven Publishers. Philadelphia, 633-646.
- Helmy A. (2000):** Retrospective analysis and study of treatment of medulloblastoma. NEMROCK experience. M.Sc., Thesis, Faculty of Medicine, Cairo, University.
- Ildan F, Cetiralp E, Bagdatoglu H et al., (1994):** Cerebellar medulloblastoma in adults. Neurosurg Rev., 17: 205-209.
- Moawad MA, (1987): Evaluation of radiotherapy in management of medulloblastoma. M.Sc. Thesis. Ain Shams University.
- Packer RJ (1999):** Childhood medulloblastoma: progress and future challenges Brain Dev, mar; 21: 2, 75-81.
- Poldnak AP and Flammery JT (1995):** Brain, other central nervous system and eye cancer. Cancer 75: 330.
- Salama M, Faris L and Abdel Hay A (1986): Management of medulloblastoma, experience in 15 years. J Egypt Nat Cancer Inst 2, No. 3: 363-371.
- Sheikh BY, Kanaan IN (1994):** Medulloblastoma in adults. J Neurol Sci. 38: 229-234.
- Sutton LN, Phillips PC, Molloy PT (1996): Surgical management of medulloblastoma. J Nueroncol; Jul, 29: 1, 9-21.
- Zelter PM, Boyett JM, Finlay JL et al., (1999):** Metastasis stage, adjuvant treatment and residual tumor as prognostic factors for medulloblastoma in children: conclusion from the children's cancer group 921 and randomized phase III study-J. Clin. Oncol.17:832

دراسة لخبرة عشرون عاماً في علاج اورام
(الميضااللو بلاستويا) بتأثيرات الدبق العصبي
(داسة بأثر رجعي على المدى البعيد)

أ.د. علاء عبد العزيز ، د. هنال معرض، أ.د. مسین بشناقر ، د. محمد قمايل.

* قسم جراحة المخ والاعصاب بطب عين شمس

** قسم علاج الاراء بالأشعاع والطب النووي بطب عين شمس

*** قسم الجراحة العامة. بطب عين شمس

ملخص البحث

يشتمل علاج مرضي بتأثيرات الدبق العصبي بعد التشخيص الحديث على الاستئصال الجرعي ثم العلاج الاشعاعي على المخ والقناة العصبية

العلاج الكيميائي المكمل ثبتت فعاليته في زيادة معدل الشفاء للمرض ذو الخطورة العالية ويعتبر علاج اساسي مكمل للمرض ذو الخطورة الوسطي.

ولقد تحسنت نتائج العلاج مع تقدم اساليب الجراحة والعلاج الاشعاعي.

ونظراً لوجود آثار جانبية لهذه الاساليب العلاجية على المدى القصير والبعيد فإن التقنية يعتبر هاماً في استخدامها للحصول على درجة قليلة من الآثار الجانبية المصاحبة للعلاج.

كان الهدف من هذا البحث هو تحليل العوامل المنذرة المختلفة والتي قد تؤثر على معدل استمرار الحياة وكذا استجابة المرض للعلاج.

ولقد شملت هذه الدراسة على 288 حالة من مرضي الميضا لليوبلاستوما والذين تم علاجهم في قسمي كل من جراحة المخ والاعصاب وعلاج الا ورام بالأشعاع والطب النووي في الفترة التي تمت بين عام 1981 حتى عام 2000.

ولقد اثبت التحليل الاحصائي الي ثبوت ان متوسط استمرار الحياة لايتاثر بالجنس او مكان الورم ولكن يتاثر بشكل كبير بدرجة الاستئصال الجراحي للورم، مرحلة الورم، عمر المريض وتحليل الانسجة، بينما تعتبر عملية تحويل السائل النخاعي من العوامل المؤثرة للتقليل من الوفاة الناتجة من التدخل الجراحي بنسبة عالية.